These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Attack of the killer clones. Scudellari M Nature; 2017 Dec; 552(7685):S64-S66. PubMed ID: 29293233 [No Abstract] [Full Text] [Related]
3. Cancer immunotherapy. Bender E Nature; 2017 Dec; 552(7685):S61. PubMed ID: 29293244 [No Abstract] [Full Text] [Related]
4. Dendritic cell vaccines for cancer immunotherapy. Timmerman JM; Levy R Annu Rev Med; 1999; 50():507-29. PubMed ID: 10073291 [TBL] [Abstract][Full Text] [Related]
5. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism. Nelson B Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750 [No Abstract] [Full Text] [Related]
6. [New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes]. Kawakami Y Nihon Naika Gakkai Zasshi; 1998 Dec; 87(12):2536-44. PubMed ID: 9922678 [No Abstract] [Full Text] [Related]
7. Genetic redirection of T cells for cancer therapy. Westwood JA; Kershaw MH J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152 [TBL] [Abstract][Full Text] [Related]
8. National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment. Bach PB N Engl J Med; 2018 Oct; 379(15):1396-1398. PubMed ID: 30110578 [No Abstract] [Full Text] [Related]
9. Cancer vaccines get a shot in the arm. Cohen J Science; 1993 Nov; 262(5135):841-3. PubMed ID: 8235605 [No Abstract] [Full Text] [Related]
10. Do no harm. Nat Biotechnol; 2013 May; 31(5):365. PubMed ID: 23657369 [No Abstract] [Full Text] [Related]
11. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future. Peinert S; Kershaw MH; Prince HM Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906 [No Abstract] [Full Text] [Related]
12. BCG as adjuvant immunotherapy for neoplasia. Hersh EM; Gutterman JU; Mavligit GM Annu Rev Med; 1977; 28():489-515. PubMed ID: 324372 [No Abstract] [Full Text] [Related]
13. The Cancer Defense. Weintraub K Sci Am; 2016 Apr; 314(4):42-51. PubMed ID: 27082190 [No Abstract] [Full Text] [Related]
14. [Cellular immunotherapy as combination partners for the immune checkpoint blockade]. Rössig C Oncol Res Treat; 2014; 37 Suppl 4():14-5. PubMed ID: 25301192 [No Abstract] [Full Text] [Related]
15. Cancer immunotherapy: Progress and challenges in the clinical setting. Zarour HM; Ferrone S Eur J Immunol; 2011 Jun; 41(6):1510-5. PubMed ID: 21618503 [No Abstract] [Full Text] [Related]
16. Manufacturing genetically modified T cells for clinical trials. Gee AP Cancer Gene Ther; 2015 Mar; 22(2):67-71. PubMed ID: 25633481 [TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy by local transfer of autologous T lymphocytes cultured with T cell growth factor and autologous tumor extract: a clinical trial. Kan N; Ohgaki K; Yamasaki N; Hori T; Nakayama N; Nio Y; Inamoto T; Hikasa Y Nihon Geka Hokan; 1983 Nov; 52(6):841-53. PubMed ID: 6380446 [No Abstract] [Full Text] [Related]
18. Current developments of immunotherapy in the clinic. Antonia S; Mulé JJ; Weber JS Curr Opin Immunol; 2004 Apr; 16(2):130-6. PubMed ID: 15023403 [TBL] [Abstract][Full Text] [Related]
19. New cancer-fighting cells enter trials. Leslie M Science; 2018 Sep; 361(6407):1056-1057. PubMed ID: 30213892 [No Abstract] [Full Text] [Related]
20. Immunotherapy of malignant melanoma. Terry WD N Engl J Med; 1980 Nov; 303(20):1174-5. PubMed ID: 6999351 [No Abstract] [Full Text] [Related] [Next] [New Search]